Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

Exclusion Criteria

• •1. History of allergy to any component of monoclonal antibodies or investigational drugs.
• •2. Central nervous system involvement.
• •3. History of previous malignant tumors.
• •4. Clinically significant cardiac or pulmonary diseases.
• •5. Infection requiring intravenous antibiotic treatment or hospitalization within 4 weeks prior to enrollment; or infection requiring oral antibiotics within 2 weeks prior to enrollment; or symptoms related to an infection within 1 week prior to enrollment.
• •6. Major surgery within 4 weeks prior to enrollment.
• •7. Vaccination with live vaccines within 4 weeks prior to enrollment or planned live vaccination during the study.
• •8. HIV antibody positive.
• •9. Active syphilis infection, TP antibody positive, and anti-TP treatment within the last 2 years.
• •10. Hepatitis C virus (HCV) antibody positive with HCV RNA quantitative test result exceeding the detection limit; Hepatitis B surface antigen (HBsAg) positive or Hepatitis B core antibody (HBcAb) positive, with Hepatitis B virus DNA quantitative test result exceeding the detection limit (for patients with HBsAg or HBcAb positive status, regardless of HBV-DNA detection, oral entecavir or other antiviral therapy must be initiated prior to enrollment and continued according to the physician's instructions during the trial).
• •11. Pregnant or breastfeeding women, or planning to become pregnant during the study.
• •12. Investigator determines the patient is unsuitable for enrollment or may not be able to complete the trial for other reasons.